Drug Trial Radar · NCT05378997
Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.
Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Apr 7, 2022
Primary completion
Mar 16, 2024
Study completion Mar 16, 2024
Sponsor
- Lead sponsor
- Xinnate ABIndustry
- Sponsor type
- Industry
- Collaborators
- Region Skane
- First posted
- May 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a three-part, Phase I, first-in-human study designed to evaluate the safety, tolerability, and potential systemic exposure of multiple topical doses of TCP-25. Part I includes healthy volunteers with acute epidermal wounds formed by the suction blister technique. Part II includes patients with non-healing leg ulcers and Part III patients with dystrophic epidermolysis bullosa (DEB).
Conditions
- Blister
- Wound of Skin
- Epidermolysis Bullosa
- Varicose Ulcer of Lower Limb
Interventions
TCP-25 gel 0.86 mg/ml or placebo gelDrug
TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
TCP-25 gel 2.9 mg/ml or placebo gelDrug
TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
TCP-25 gel 8.6 mg/ml or placebo gelDrug
TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 15 days in Part I (modified endpoints & timeframes in Part II & III)
- Incidence of abnormal local reactions (Local tolerability)Time frame: Day 1 in Part I (modified endpoints & timeframes in Part II & III)
- Incidence of abnormal local reactions (Local tolerability)Time frame: Day 2 in Part I (modified endpoints & timeframes in Part II & III)
- Incidence of abnormal local reactions (Local tolerability)Time frame: Day 3 in Part I (modified endpoints & timeframes in Part II & III)
- Incidence of abnormal local reactions (Local tolerability)Time frame: Day 5 in Part I (modified endpoints & timeframes in Part II & III)
- Incidence of abnormal local reactions (Local tolerability)Time frame: Day 8 in Part I (modified endpoints & timeframes in Part II & III)
- Incidence of abnormal local reactions (Local tolerability)Time frame: Day 11 in Part I (modified endpoints & timeframes in Part II & III)
- Incidence of abnormal local reactions (Local tolerability)Time frame: Day 15 in Part I (modified endpoints & timeframes in Part II & III)
- Number of patients with clinically significant changes from baseline in electrocardiogram (ECG)Time frame: During screening (baseline) and on day 11 in Part I (modified endpoints & timeframes in Part II & III)
- Number of patients with clinically significant changes from baseline in vital signs.Time frame: During screening (baseline) and on day 11 in Part I (modified endpoints & timeframes in Part II & III)
- Number of patients with clinically significant changes from baseline in physical examinationsTime frame: During screening (baseline) and on day 11 in Part I (modified endpoints & timeframes in Part II & III)
- Number of patients with clinically significant changes from baseline in safety laboratory parametersTime frame: During screening (baseline) and on day 2 in Part I (modified endpoints & timeframes in Part II & III)
- Number of patients with clinically significant changes from baseline in safety laboratory parametersTime frame: During screening (baseline) and on day 3 in Part I (modified endpoints & timeframes in Part II & III)
- Number of patients with clinically significant changes from baseline in safety laboratory parametersTime frame: During screening (baseline) and on day 5 in Part I (modified endpoints & timeframes in Part II & III)
- Number of patients with clinically significant changes from baseline in safety laboratory parametersTime frame: During screening (baseline) and on day 11 in Part I (modified endpoints & timeframes in Part II & III)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Skåne University Hospital in Lund, Clinical Trial Unit
Lund, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.